Literature DB >> 27482827

Sex-Dimorphic Effects of Prenatal Treatment With Dexamethasone.

Lena Wallensteen1, Marius Zimmermann1, Malin Thomsen Sandberg1, Anton Gezelius1, Anna Nordenström1, Tatja Hirvikoski1, Svetlana Lajic1.   

Abstract

CONTEXT: Dexamethasone (DEX) is used to prevent virilization in female fetuses at risk of congenital adrenal hyperplasia (CAH). Given that treatment has to be started before the genotype is known, 7 out of 8 fetuses will be exposed to DEX without benefit.
OBJECTIVE: To evaluate long-term cognitive effects of prenatal DEX therapy in healthy (non-CAH) DEX-treated children. DESIGN AND
SETTING: Observational study with patient and control groups from a single research institute. PARTICIPANTS: Healthy (non-CAH) DEX-treated subjects (n = 34) and untreated population controls (n = 66) from Sweden, aged 7-17 years. INTERVENTION: DEX-treatment used in unborn children at risk of CAH, during first trimester of fetal life. MAIN OUTCOME MEASURES: Standardized neuropsychological tests and questionnaires were used.
RESULTS: DEX treatment has widespread negative effects in girls. In Wechsler Intelligence Scales for Children-III scale subtests, we observed significant interactions between DEX and GENDER (coding, P = .044; block design, P = .013; vocabulary, P = .025) and a trend for the subtest digit span (P = .074). All interactions were driven by DEX effects in girls, but not boys, with DEX-treated females showing lower scores than female untreated controls (coding, P = .068, d = 0.66; block design, P = .021, d = 0.81; vocabulary, P = .014, d = 0.84; digit span, P = .001, d = 1.0). Likewise, DEX-treated girls tend to have poorer visual spatial working memory performance than controls (span board test forward: P = .065, d = .80). We observed no effects on long-term memory, handedness, speed of processing, nor self-perceived or parentally reported scholastic performance.
CONCLUSIONS: Early prenatal DEX exposure affects cognitive functions in healthy girls, ie, children who do not benefit from the treatment. It can therefore not be considered safe to use this therapy in the context of CAH.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27482827     DOI: 10.1210/jc.2016-1543

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Congenital Adrenal Hyperplasia.

Authors:  Selma Feldman Witchel
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-04-24       Impact factor: 1.814

Review 2.  Challenges in Prenatal Treatment with Dexamethasone.

Authors:  Bonnie McCann-Crosby; Frank Xavier Placencia; Oluyemisi Adeyemi-Fowode; Jennifer Dietrich; Rachel Franciskovich; Sheila Gunn; Marni Axelrad; Duong Tu; David Mann; Lefkothea Karaviti; Vernon Reid Sutton
Journal:  Pediatr Endocrinol Rev       Date:  2018-09

Review 3.  Let's call the whole thing off: evaluating gender and sex differences in executive function.

Authors:  Nicola M Grissom; Teresa M Reyes
Journal:  Neuropsychopharmacology       Date:  2018-08-14       Impact factor: 7.853

4.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

5.  Antenatal Dexamethasone Treatment Induces Sex-dependent Upregulation of NTPDase1/CD39 and Ecto-5'-nucleotidase/CD73 in the Rat Fetal Brain.

Authors:  Milica Manojlovic-Stojanoski; Irena Lavrnja; Ivana Stevanovic; Svetlana Trifunovic; Natasa Ristic; Natasa Nestorovic; Jean Sévigny; Nadezda Nedeljkovic; Danijela Laketa
Journal:  Cell Mol Neurobiol       Date:  2021-03-24       Impact factor: 5.046

Review 6.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

7.  Programming for increased expression of hippocampal GAD67 mediated the hypersensitivity of the hypothalamic-pituitary-adrenal axis in male offspring rats with prenatal ethanol exposure.

Authors:  Juan Lu; Zhexiao Jiao; Ying Yu; Chong Zhang; Xia He; Qiang Li; Dan Xu; Hui Wang
Journal:  Cell Death Dis       Date:  2018-05-31       Impact factor: 8.469

Review 8.  46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features.

Authors:  Federico Baronio; Rita Ortolano; Soara Menabò; Alessandra Cassio; Lilia Baldazzi; Valeria Di Natale; Giacomo Tonti; Benedetta Vestrucci; Antonio Balsamo
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

9.  First-Trimester Prenatal Dexamethasone Treatment Is Associated With Alterations in Brain Structure at Adult Age.

Authors:  Annelies Van't Westeinde; Leif Karlsson; Anna Nordenström; Nelly Padilla; Svetlana Lajic
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 6.134

Review 10.  Caring for individuals with a difference of sex development (DSD): a Consensus Statement.

Authors:  Martine Cools; Anna Nordenström; Ralitsa Robeva; Joanne Hall; Puck Westerveld; Christa Flück; Birgit Köhler; Marta Berra; Alexander Springer; Katinka Schweizer; Vickie Pasterski
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.